Sartorius Aktiengesellschaft (ETR:SRT3)

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2025	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
EMEA Revenue	1.43B	1.47B	1.39B
EMEA Revenue Growth	-2.50%	5.59%	5.55%
Americas Revenue	1.24B	1.25B	1.20B
Americas Revenue Growth	-1.29%	4.32%	-6.31%
Asia Pacific Revenue	802.60M	820.10M	792.30M
Asia Pacific Revenue Growth	-2.13%	3.51%	-0.89%
Revenue (Other)	-100.00K	-	-100.00K
Revenue (Total)	3.47B	3.54B	3.38B
Revenue (Total) Growth	-1.99%	4.66%	-0.44%

Revenue

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2025	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Bioprocess Solutions Revenue	2.79B	2.87B	2.69B
Bioprocess Solutions Revenue Growth	-2.48%	6.50%	0.45%
Lab Products & Services Revenue	673.70M	673.00M	690.50M
Lab Products & Services Revenue Growth	0.10%	-2.53%	-3.76%
Revenue (Other)	-	100.00K	-
Revenue (Total)	3.47B	3.54B	3.38B
Revenue (Total) Growth	-1.99%	4.66%	-0.44%

EBITDA

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2025	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Bioprocess Solutions Underlying EBITDA	851.50M	907.00M	787.20M
Bioprocess Solutions Underlying EBITDA Growth	-6.12%	15.22%	0.63%
Lab Products & Services Underlying EBITDA	149.70M	144.60M	158.10M
Lab Products & Services Underlying EBITDA Growth	3.53%	-8.54%	-12.31%
Operating Income (Total)	432.90M	542.60M	392.60M
Operating Income (Total) Growth	-20.22%	38.21%	-22.20%

Key Performance Indicators

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Bioprocess Solutions Order Intake	2.69B
Bioprocess Solutions Order Intake Growth	12.02%
Lab Products & Services Order Intake	684.40M
Lab Products & Services Order Intake Growth	3.26%
Total Order Intake	3.38B
Total Order Intake Growth	10.13%

Updated Apr 23, 2026. Data Source: Fiscal.ai.